RT Journal Article SR Electronic T1 Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 217 OP 221 DO 10.21873/anticanres.16152 VO 43 IS 1 A1 KIKUCHI, MAMI A1 FUJII, TAKAAKI A1 HONDA, CHIKAKO A1 TANABE, KEIKO A1 NAKAZAWA, YUKO A1 OGINO, MISATO A1 OBAYASHI, SAYAKA A1 SHIRABE, KEN YR 2023 UL http://ar.iiarjournals.org/content/43/1/217.abstract AB Background/Aim: Despite advances in the treatment of breast cancer, metastatic breast cancer (MBC) remains difficult to cure, and few MBC patients survive 10 years after receiving a breast cancer metastasis diagnosis. We collected the cases of patients with MBC who survived >10 years post-metastasis diagnosis and assessed the patients’ characteristics. Patients and Methods: We retrospectively analyzed the cases of 245 consecutive patients diagnosed with MBC between January 2005 and December 2012 at our institution. Among them, 167 patients with confirmed survival of >10 years (i.e., long-term survival) or confirmed death at ≤10 years post-metastasis diagnosis were enrolled. Results: There were 22 patients with MBC who survived >10 years. Regarding the cancer subtypes, 11 patients (50%) with long-term survival were HER2-positive. Seven of the 11 patients with HER2-positive MBC have been without recurrence although anti-HER2 therapy was discontinued. Triple-negative breast cancer (TNBC) was most common in the patients who survived ≤5 years but was not present in the >10-year survival group. In the HER2-negative cases, more cases in the long-term survival group were treated with local therapy (34.4% in the <5-year survival group, 43.8% in the 5-10-year group, and 72.7% in the >10-year group). Conclusion: MBC patients who survive >10 years after being diagnosed with metastasis are more likely to be HER2-positive and treated with local therapy. This suggests the efficacy of anti-HER2 therapy, and, conversely, clarifies unmet needs in TNBC and luminal-type MBC. The usefulness of local therapy was also supported by our findings.